Atopic dermatitis: Baricitinib ‘shows long-term efficacy’
An extension study shows response to the oral Janus kinase inhibitor can be maintained for 16 months in about half of responders
The rheumatoid-arthritis drug baricitinib reduces symptoms of moderate to severe atopic dermatitis (AD) for at least 68 weeks, according to an extension study of two randomised controlled trials.
BREEZE-AD3 is an ongoing, double-blind extension of the earlier phase-3 BREEZE-AD1 and BREEZE-AD2 trials and is taking place at sites across Europe, Asia, Latin America, and Australia.
Patients classified as responders or partial responders in the earlier (16-week) studies were eligible to enrol in BREEZE-AD3.
Responders and partial responders had scores of 0 or 1 and 2, respectively, on the validated Investigator Global Assessment for atopic dermatitis (vIGA-AD) and had not received rescue therapy during the original studies.
